SRR11296877
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.390
- NOTCH_SIGNALING+0.340
- TGF_BETA_SIGNALING+0.290
- BILE_ACID_METABOLISM+0.250
- ESTROGEN_RESPONSE_LATE+0.200
- ESTROGEN_RESPONSE_EARLY+0.180
- CHOLESTEROL_HOMEOSTASIS+0.170
- HEDGEHOG_SIGNALING+0.110
- APOPTOSIS+0.090
- P53_PATHWAY+0.090
Top 10 suppressed
- INTERFERON_GAMMA_RESPONSE-0.390
- E2F_TARGETS-0.340
- INTERFERON_ALPHA_RESPONSE-0.340
- COMPLEMENT-0.320
- MYC_TARGETS_V1-0.320
- MYC_TARGETS_V2-0.320
- ALLOGRAFT_REJECTION-0.310
- MTORC1_SIGNALING-0.300
- IL6_JAK_STAT3_SIGNALING-0.280
- ANGIOGENESIS-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-B6-A0RQ-01A-11R-A115-07 | — | A | 0.840 |
| 2 | TCGA-BH-A0DO-01B-11R-A12D-07 | — | A | 0.829 |
| 3 | TCGA-AN-A0XT-01A-11R-A109-07 | — | B | 0.825 |
| 4 | s0112264 | — | — | 0.824 |
| 5 | s0122235 | — | — | 0.812 |
| 6 | TCGA-OL-A5RV-01A-12R-A28M-07 | — | A | 0.809 |
| 7 | SRR27320668 | — | — | 0.805 |
| 8 | MNG660 | — | — | 0.800 |
| 9 | s0112300 | — | — | 0.794 |
| 10 | TCGA-BH-A0E9-01B-11R-A115-07 | — | A | 0.791 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.390 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.340 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.290 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.180 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.170 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.110 | Inavolisib | — uncovered |
| APOPTOSIS | 0.090 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.090 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.060 | Temsirolimus | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.040 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.030 | Cobimetinib | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |